Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6

RF Tyndale, R Sunahara, T Inaba, W Kalow, FJ Gonzalez and HB Niznik

Department of Pharmacology, University of Toronto, Ontario, Canada.

Catalytic, pharmacological, and molecular criteria have been used to identify cytochrome P450IID1 in mammalian brain (enzyme, P450IID; gene, CYP2D). Sparteine metabolism in canine striatal membranes was shown to be inhibited in a concentration-dependent and stereoselective manner by quinidine (Ki, approximately 51 nM), quinine (Ki, approximately 5.9 microM), and various other known substrates and inhibitors of hepatic P450IID1 activity. In addition, canine striatal P450IID1 was inhibited with high affinity by dopamine uptake blockers, such as (-)-cocaine (Ki, approximately 74 nM), d-amphetamine (Ki, approximately 4.5 microM), and methylphenidate (Ki, approximately 15 microM). Inhibitory constants (Ki) of numerous compounds for inhibition of sparteine metabolism in canine striatal membranes correlated well with (a) Ki values observed in human liver microsomes (r = 0.95), (b) [3H]GBR-12935 binding to P450IID1 in canine striatal membranes (r = 0.85), and (c) the inhibition (IC50) of sparteine metabolism in HepG2 cells expressing human CYP2D6 cDNA (r = 0.93). Moreover, antibodies raised against rat hepatic enzyme inhibited, in a concentration-dependent manner, sparteine metabolism in canine striatal membranes. Enzymatic activity was unevenly distributed throughout the canine brain and ranged from 0.5 to 21 pmol/mg of protein/hr in cerebellum and supraorbital cortex, respectively, with the striatum displaying moderate levels of activity (8 pmol/mg of protein/hr). The polymerase chain reaction was used to amplify cDNA from a human caudate lambda gt11 library encoding exons 6- 9 of the human CYP2D6 gene, which revealed, upon sequencing, 100% nucleic acid sequence identity. These data indicate that P450IID1 is expressed centrally and is similar, at the functional and molecular levels, to the human hepatic P450IID1 enzyme. Because the debrisoquine/sparteine mono-oxygenase is a polymorphic enzyme, in which 5-10% of caucasians are deficient in metabolism of various drugs, a genetic difference in human brain metabolism of P450IID1 substrates may possibly lead to differences in drug response and toxicity.

Volume 40, Issue 1, pp. 63-68, 07/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				H. Shen, M. M. He, H. Liu, S. A. Wrighton, L. Wang, B. Guo, and C. Li Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17 Drug Metab. Dispos., August 1, 2007; 35(8): 1292 - 1300. [Abstract] [Full Text] [PDF]

				G. McKeown-Eyssen, C. Baines, D. E. Cole, N. Riley, R. F Tyndale, L. Marshall, and V. Jazmaji Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR Int. J. Epidemiol., October 1, 2004; 33(5): 971 - 978. [Abstract] [Full Text] [PDF]

				M J Le Nedelec and R J Rosengren Methylphenidate inhibits cytochrome P450 in the Swiss Webster mouse Human and Experimental Toxicology, May 1, 2002; 21(5): 273 - 280. [Abstract] [PDF]

				D. G. Williams, D. J. Hatch, and R. F. Howard Codeine phosphate in paediatric medicine Br. J. Anaesth., March 1, 2001; 86(3): 413 - 421. [Abstract] [Full Text] [PDF]

				T. Coleman, E. F. Spellman, A. Rostami-Hodjegan, M. S. Lennard, and G. T. Tucker The 1'-Hydroxylation of rac-Bufuralol by Rat Brain Microsomes Drug Metab. Dispos., September 1, 2000; 28(9): 1094 - 1099. [Abstract] [Full Text]

				G. Emilien, M. Ponchon, C. Caldas, O. Isacson, and J.-M. Maloteaux Impact of genomics on drug discovery and clinical medicine QJM, July 1, 2000; 93(7): 391 - 423. [Abstract] [Full Text] [PDF]

				R. F. Tyndale, Y. Li, N.-Y. Li, E. Messina, S. Miksys, and E. M. Sellers Characterization of Cytochrome P-450 2D1 Activity in Rat Brain: High-Affinity Kinetics for Dextromethorphan Drug Metab. Dispos., August 1, 1999; 27(8): 924 - 930. [Abstract] [Full Text]

				R. S. Obach, J. Pablo, and D. C. Mash Cytochrome P4502D6 Catalyzes the O-Demethylation of the Psychoactive Alkaloid Ibogaine to 12-Hydroxyibogamine Drug Metab. Dispos., August 1, 1998; 26(8): 764 - 768. [Abstract] [Full Text]

				J. Loeper, B. Louérat-Oriou, C. Duport, and D. Pompon Yeast Expressed Cytochrome P450 2D6 (CYP2D6) Exposed on the External Face of Plasma Membrane Is Functionally Competent Mol. Pharmacol., July 1, 1998; 54(1): 8 - 13. [Abstract] [Full Text]

				R. M. Lane SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment J Psychopharmacol, January 1, 1998; 12(2): 192 - 214. [Abstract] [PDF]

				B. J. Goldstein and P. J Goodnick Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics J Psychopharmacol, January 1, 1998; 12(4_suppl): 55 - S87. [Abstract] [PDF]

				W. Kalow Pharmacogenetics in Biological Perspective Pharmacol. Rev., December 1, 1997; 49(4): 369 - 380. [Abstract] [Full Text] [PDF]